Annual Drug Patent Expirations for DALIRESP
Daliresp is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for DALIRESP.
This drug has seventy-nine patent family members in thirty-six countries.
The generic ingredient in DALIRESP is roflumilast. One supplier is listed for this compound. Additional details are available on the roflumilast profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
